Fidelity's increased passive stake signals continued institutional confidence following the RASONQUE launch. Monitor for any future conversion to a 13D filing, which would indicate activist intent.
RVMD drugs
RVMD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $177.65entry
- T+1 · 11d ago +8.24%α +7.92% · $192.28
- T+5 · 5d ago −0.73%α −4.02% · $176.35
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 7.2% passive stake in Revolution Medicines as of September 30, 2026, up from a prior filing. The increase reflects Fidelity's continued accumulation following the company's strong Q3 earnings beat from its newly approved drug RASONQUE.
Key Financial Metrics
Key Facts
- FMR LLC (Fidelity) reported beneficial ownership of 15,402,102.97 shares of Revolution Medicines common stock as of September 30, 2026.
- The stake represents 7.2% of shares outstanding.
- This is an amendment to a prior Schedule 13G filing, indicating an increase from the previously reported position.
- The filing is passive (Rule 13d-1(b)), with no intent to influence control.
- Fidelity Management & Research Company LLC is the entity that beneficially owns 5% or greater of the outstanding shares.
Financial Impact
FMR LLC holds 15.4 million shares valued at approximately $3.0B based on the $41.6B market cap and 7.2% stake.
Risk Factors
- Passive filing status means Fidelity has no current intent to influence management or strategy.
- No information on the exact change in share count from the prior filing is provided in this document.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002851 |
| Document: 0000315066-26-002851-index-headers.html | 0000315066-26-002851 |
| Document: 0000315066-26-002851-index.html | 0000315066-26-002851 |
| Document: 0000315066-26-002851.txt | 0000315066-26-002851 |
Track record
44 reports on RVMD
7 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +31.56% at T+60 after the Apr 21, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $167.00 Now $166.87 −0.08% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $168.20 Now $166.87 −0.79% settles Feb 12
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $176.02 Now $166.87 −5.20% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $176.35 Now $166.87 −5.38% settles Feb 10
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Viewing Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $177.65 Now $166.87 −6.07% settles Feb 3
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $191.31 Now $166.87 −12.78% settles Jan 28
- Oct 23, 202624d ago Institutional Cluster Bullish 4/10 Entry $186.99 Now $166.87 −10.76% settles Jan 21
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $187.69 Now $166.87 −11.09% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers